title: Apolipoprotein E epsilon4 allele frequency in elderly depressed patients with and without cerebrovascular disease.
abstract: Late-onset depression (LOD) could be a very early manifestation of Alzheimer's disease (AD), although contradictory results have been reported. Cerebrovascular disease (CVD) may favor the development of LOD, and that the particular forms of vascular depression should be individualized. The Apolipoprotein E (ApoE) epsilon4 allele was shown to be a risk factor for AD. Its role in LOD is controversial, while it is still unknown in vascular depression. Our objective was to clarify the relationship between ApoE epsilon4 allele and LOD in patients with and without CVD. We examined the ApoE phenotypes in a sample of 311 subjects: 50 with vascular LOD, 24 with LOD without CVD, 115 with AD and 122 normal controls (NC). The study of the ApoE epsilon4 allele frequency showed significant differences between: AD group and the vascular LOD and NC groups; LOD group without CVD compared with NC group (p<0.05 to 0.001). The frequency of the epsilon4 allele in the LOD group without CVD did not differ significantly from the AD group, similarly the frequency of the epsilon4 allele in the vascular LOD group was not different from that in NC. The study suggests an association between the ApoE epsilon4 allele and the LOD without CVD. These patients could be at risk of developing AD by an epsilon4-dependent pathway. In contrast, the results show no association between the presence of ApoE epsilon4 allele and vascular depression and provide further evidence in support of the concept that ApoE epsilon4 allele is not associated with clinical CVD.
authors.affiliation: Hôpital Broca, Paris, France. traykov_i@yahoo.fr
authors.forename: Latchezar
authors.initials: L
authors.lastname: Traykov
authors.forename: Anne Catherine
authors.initials: AC
authors.lastname: Bayle
authors.forename: Florence
authors.initials: F
authors.lastname: Latour
authors.forename: Hermine
authors.initials: H
authors.lastname: Lenoir
authors.forename: Marie-Laure
authors.initials: ML
authors.lastname: Seux
authors.forename: Olivier
authors.initials: O
authors.lastname: Hanon
authors.forename: Renaud
authors.initials: R
authors.lastname: Péquignot
authors.forename: Pierre
authors.initials: P
authors.lastname: Bert
authors.forename: Florence
authors.initials: F
authors.lastname: Moulin
authors.forename: Inge
authors.initials: I
authors.lastname: Cantegreil
authors.forename: Emilie
authors.initials: E
authors.lastname: Wenisch
authors.forename: Fériel
authors.initials: F
authors.lastname: Batouche
authors.forename: Shima
authors.initials: S
authors.lastname: Mehrabian
authors.forename: Jocelyne de
authors.initials: Jd
authors.lastname: Rotrou
authors.forename: Anne-Sophie
authors.initials: AS
authors.lastname: Rigaud
mesh_terms: D017668:Age of Onset; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000235:genetics* / Q000523:psychology; D000544:Alzheimer Disease / Q000150:complications / Q000235:genetics*; D053327:Apolipoprotein E4 / Q000235:genetics*; D002561:Cerebrovascular Disorders / Q000150:complications / Q000235:genetics* / Q000523:psychology; D004252:DNA Mutational Analysis; D003866:Depressive Disorder / Q000150:complications / Q000235:genetics*; D042241:Early Diagnosis; D005260:Female; D005787:Gene Frequency / Q000235:genetics; D005819:Genetic Markers; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D005820:Genetic Testing; D005838:Genotype; D006801:Humans; D008297:Male; D010641:Phenotype; D011110:Polymorphism, Genetic / Q000235:genetics; D011237:Predictive Value of Tests; D011379:Prognosis; D012307:Risk Factors
chemical_list: D053327:Apolipoprotein E4; D005819:Genetic Markers